See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

Teaching Aids for Health Educators

Barbara George

Teaching Aids for Health Educators

Peer Support from DiabetesSisters

Brandy Barnes, Founder and CEO - DiabetesSisters.org

Peer Support from DiabetesSisters

STAT™ Medical Devices

Roger Huckleberry

STAT™ Medical Devices

Novo Nordisk

Page 3
Hypoglycemia Affects Productivity at Work
Feb 21, 2012 | 
A survey of type 1 and type 2 diabetes patients in the United States, United Kingdom, France, and Germany indicates that more than one in every five have arrived late at work or not shown up at all because of a hypoglycemic episode the night before.
FDA Gives Long-Awaited Nod to Amylin’s Bydureon
Feb 3, 2012 | 
After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year.
DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

Teaching Aids for Health Educators

Barbara George

Teaching Aids for Health Educators

Peer Support from DiabetesSisters

Brandy Barnes, Founder and CEO - DiabetesSisters.org

Peer Support from DiabetesSisters

STAT™ Medical Devices

Roger Huckleberry

STAT™ Medical Devices

Novo Says Early Use of Victoza Aids Type 2 Control
Dec 15, 2011 | 
News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy Type 2 Diabetes" for more discussion about the phenomenon.)
Novo Nordisk Files for FDA Approval of New Insulin
Oct 15, 2011 | 
A brand new insulin will soon be on pharmacy shelves in the United States if Danish pharmaceutical company Novo Nordisk has its way. The company has filed for approval from the Food and Drug Administration to sell insulin degludec, an original formulation that lasts an extra-long time. Insulin degludec is injected only once a day. Once under the skin, the dose of insulin is absorbed slowly and consistently, allowing for better nighttime control, according to Novo. Most importantly, test subjects had a low rate of hypoglycemia on the drug.
Novo Says Early Use of Victoza Aids Type 2 Control
Oct 2, 2011 | 
News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes" for more discussion about this phenomenon.) In a study it released in Lisbon, Portugal, at the recent meeting of the European Association for the Study of Diabetes, Novo said that combining its recently released drug Victoza® (liraglutide) with another drug early in therapy helps recently diagnosed type 2s achieve greater blood glucose control than they can with a single drug.
The State of Insulin Injection
Sep 11, 2011 | 
What's Being Researched Now
Type 2 Drug Victoza Helps Type 1s, Too
Jul 11, 2011 | 
Victoza, a drug aimed at type 2 diabetes, may turn out to be a boon for type 1 diabetes patients as well. A small clinical study shows that patients with well-controlled type 1 who took Victoza daily for just one week experienced a 15 percent drop in their blood sugar levels. Patients who took the drug over a full 24-week test period needed less and less insulin, decreasing their average mealtime dose by seven units and their all-day insulin requirement by eight.
Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.